These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Flat intraurothelial lesions of the urinary bladder-do hyperplasia, dysplasia, and atypia of unknown significance need to exist as diagnostic entities? and how to handle in routine clinical practice. Paner GP; Smith SC; Hartmann A; Agarwal PK; Compérat E; Amin MB Mod Pathol; 2022 Oct; 35(10):1296-1305. PubMed ID: 35468997 [TBL] [Abstract][Full Text] [Related]
4. Bladder Tumor Subtype Commitment Occurs in Carcinoma Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889 [TBL] [Abstract][Full Text] [Related]
5. Urothelial dysplasia of the bladder: diagnostic features and clinical significance. Lopez-Beltran A; Montironi R; Vidal A; Scarpelli M; Cheng L Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):121-9. PubMed ID: 24344498 [TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin. Scott SN; Ostrovnaya I; Lin CM; Bouvier N; Bochner BH; Iyer G; Solit D; Berger MF; Lin O Cancer Cytopathol; 2017 Jun; 125(6):416-426. PubMed ID: 28339163 [TBL] [Abstract][Full Text] [Related]
7. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions. Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577 [TBL] [Abstract][Full Text] [Related]
9. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hodges KB; Lopez-Beltran A; Davidson DD; Montironi R; Cheng L Hum Pathol; 2010 Feb; 41(2):155-62. PubMed ID: 19762067 [TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of non-coding and coding DNA mutations in flat urothelial lesions: biological implications and insights. Musangile FY; Matsuzaki I; Iwamoto R; Sagan K; Nishikawa M; Mikasa Y; Takahashi Y; Higashine R; Kojima F; Hara I; Murata SI Virchows Arch; 2024 Aug; ():. PubMed ID: 39167111 [TBL] [Abstract][Full Text] [Related]
11. [Revisions in the WHO histological classification of urothelial bladder tumors and flat urothelial lesions]. Helpap B; Köllermann J Pathologe; 2000 May; 21(3):211-7. PubMed ID: 10900613 [TBL] [Abstract][Full Text] [Related]
12. Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. Garczyk S; Ortiz-Brüchle N; Schneider U; Lurje I; Guricova K; Gaisa NT; Lorsy E; Lindemann-Docter K; Heidenreich A; Knüchel R Am J Pathol; 2020 Feb; 190(2):323-332. PubMed ID: 31734230 [TBL] [Abstract][Full Text] [Related]
13. [So-called "superficial" bladder tumors. Which classification in 2003? Part 2: Flat urothelial lesions]. Sibony M; Billerey C Ann Pathol; 2003 Feb; 23(1):35-45. PubMed ID: 12743498 [TBL] [Abstract][Full Text] [Related]
14. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma. Mai KT; Busca A; Belanger EC Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746 [TBL] [Abstract][Full Text] [Related]
16. Use of Artificial Intelligence for the Interpretable Prediction of the Pathologic Diagnosis and Molecular Abnormalities of Flat Urothelial Lesions. Nishikawa T; Matsuzaki I; Ryuta I; Musangile FY; Sagan K; Nishikawa M; Mikasa Y; Takahashi Y; Kojima F; Murata SI Am J Pathol; 2023 Jan; 193(1):39-50. PubMed ID: 36341995 [TBL] [Abstract][Full Text] [Related]
17. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. McKenney JK; Gomez JA; Desai S; Lee MW; Amin MB Am J Surg Pathol; 2001 Mar; 25(3):356-62. PubMed ID: 11224606 [TBL] [Abstract][Full Text] [Related]
18. Urothelial carcinoma in situ: diagnostic update. McKenney JK Pathology; 2021 Jan; 53(1):86-95. PubMed ID: 33234229 [TBL] [Abstract][Full Text] [Related]
19. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. McKenney JK; Desai S; Cohen C; Amin MB Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap. Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]